RxDoctor Payments Data

Robert Fantus, MD

Ophthalmology · Skokie, ILNPI 1356873970

Payments from drug & device makers

$2,039in general payments, 2019–2025

Across 35 payments — averaging $58.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$794
  • NEW World Medical,inc.$305
  • Amgen$221
  • Sight Sciences, Inc.$165
  • Bausch & Lomb Americas Inc.$150
  • AbbVie$118
  • plus $285 from 5 others

What the payments were for

  • Food & beverage$2,039100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,039 in reported general payments places this provider in the 55th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$178,961
Medicare patients
585
Services billed
1,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine129$162,965
XiidraLifitegrast60$55,890
CequaCyclosporine52$39,130
Cyclosporine70$29,691
Prednisolone Acetate360$13,514
MoxifloxacinMoxifloxacin Hcl246$4,689
Ketorolac Tromethamine158$2,946
Latanoprost192$2,674
Timolol Maleate65$2,481
Brimonidine Tartrate36$2,451
Fluorometholone19$1,311
ValacyclovirValacyclovir Hcl32$1,112
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat60$1,065
Azelastine Hcl12$943
Dorzolamide Hcl14$322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$118$162,965129 claims
Bausch & Lomb Americas Inc.Xiidra$150$55,89060 claims
Sun Pharmaceutical Industries Inc.Cequa$62$39,13052 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Skokie

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →